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ABSTRACT 
The in vitro activity of twelve cephalosporins 
(first generation: Cephalothin, Cefazolin; second 
generation: Cefoxitin, Cefamandole, Cefuroxime, 
Cefonicid; third generation: Ceftazidime, Ceftizoxime, 
Cefotaxime, Cefoperazone, Ceftriaxone, Moxalactam) were 
studied against 146 strains of Gram negative bacilli 
belonging to the following families: 
Enterobacteriaceae Proteus vulgaris (2), 1:_, mirabilis 
(5), Providencia stuartii (6), ~ alkalifaciens (5), 
Morqanella morganii (16), Serratia marcescens (14), 
Enterobacter cloacae (17), ~ aerogenes (9), Kluyvera 
ascorbata ( 3), Ci trobacter freundii (14), .£., diversus 
(3), ~ amalonaticus (1), Yersinia intermedia (1), Y. 
enterocolitica (2); Pseudomonadaceae: Pseudomonas 
aeruginosa (31), 1:_, fluorescens (3); Neisseriaceae: 
Acinetobacter anitratus (3), Acinetobacter lwoffi (1); 
and Vibrionaceae: Aeromonas hydrqphilia (4), 
Plesiomonas shigelloides (1), Campylobacter ieiuni 
( 5 ) ) . 
This investigation, which studied the activity of 
all the mentioned cephalosporins against each strain, 
suggests that resistance to the third generation 
cephalosporins has already emerged in such species as 
§.. marcescens, ;!;;_. cloacae, ~ aerogenes, £.. freundii, 
E· aeruginosa, f. fluorescens, b· anitratus, b· lwoffi, 
v 
and Campylobacter jejuni. This resistance is most 
pronounced in Enterobacter spp., Serratia marcescens, 
and Pseudomonas aeruginosa. The second generation 
cephalosporins, particularly Cefoxitin and perhaps 
Cefuroxime, are chief inducers of resistance in 
Enterobacter and Serratia. In the pseudomonads 
----------=d=i~f~f~e=r~ent mechanisms seem to operate than those taking 
place in Enterobacter-Serratia. 
The study also shows that resistance is not a 
generic characteristic in Proteus, Providencia, or 
Citrobacter but rather specific. Some aspects of 
mechanisms of resistance to cephalosporins are 
discussed. Concern is here indicated that at least in 
certain groups of bacteria, the use of the second 
generation cephalosporins may lead to emergence of 
resistance to the third generation group. 
vi 
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INTRODUCTION 
Reports on in vitro testing of clinical isolates 
are abundant in the literature; antibiograms for many 
commonly encountered species are published routinely 
(usually annually) by microbiology departments of all 
ma--:j-oJ?-h.-Gsp-i-t-a-1-s-i-n--t-he---C-Ountry. __ f_or __ i n::_hou s _e _____ u s __ e ____ by_ __ t_h~-------------
medical and pharmaceutical staff. These antibiograms 
include representatives of all antimicrobial drugs 
including the cephalosporins. Rarely, however, all 
members of what have come to be referred to as first, 
second, and third generation cephalosporins are 
included; usually one (or two representatives) of each 
cephalosporin group is selected for testing. Quite 
often, the antibiotics that are included are determined 
by a hospital committee representing the medical, 
pharmaceutical, and microbiological staff. A 
physician, therefore, is expected to prescribe drugs 
that are available in a "closed formulary" in the 
pharmacy. This is not the case at Dameron Hospital in 
Stockton, California. Because of an "open formulary" 
and because physicians are free to prescribe what they 
believe should be used, the microbiology department at 
Dameron Hospital attempts to test bacterial isolates 
against a large number of antimicrobial drugs and a 
much larger group of cephalosporins than usually tested 
at many other hospitals. 
During the preparation of the 1984 antibiogram, 
Nahhas (1985 - personal communication) observed that 
although most bacterial species react the same way 
(either susceptible or resistant) to all members of the 
first generation cephalosporins, certain isolates react 
differently to the various members of the second 
generation group. Little information was available at 
the time with respect to the third generation 
cephalosporins. He suggested that I undertake this 
investigation as a possible thesis research project. 
Literature review revealed that differences in 
susceptibility to the cephalosporins do exist in some 
bacterial species; it also showed that little or no 
information was available for some species because they 
are rarely encountered, and that, where cephalosporins 
were tested, usually no more than 3-5 were included. 
It was also apparent that some new information may be 
revealed if a single isolate was tested against "all'' 
the cephalosporins and not just "representatives" of 
each group. It is hoped that my results, based on 
above, might contribute to an understanding of the 
basis of susceptibility or resistance to the 
cephalosporins, at least as it relates to the selected 
bacteria in this study. It is also hoped that a 
baseline could be established for future comparisons. 
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HISTORICAL REVIEW 
The cephalosporins, like the penicillins, are a 
group of antibiotics whose specific action is 
inhibition of cell wall synthesis by blocking the cross 
l ±-nk-i-ng---o-f--t-h-e- -1-i nea-~-p ep-t-idog ly can _l_ay_e_r_s ____ in ___ tlle __ _  
bacterial cell wall. Since neither the pepticoglycan 
components, nor the enzymes for peptidoglycan sythesis 
are found in eukaryotic organisms, the cephalosporins 
and the penicillins have a specific mode of action 
restricted to bacteria, and more specifically, 
bacterial cell walls, whether Gram positive or Gram 
negative. 
Credit for the discovery of cephalosporin 
antibacterial activity is given to Professor Guiseppi 
Brotzu of Cagliari University in Sardinia, Italy 
(Abraham, 1979). In 1945 Professor Brotzu isolated from 
seawater a species of Cephalosporium identified as C. 
acremonium (Class Ascomycetes, Order Spheriales, Family 
Ophiostomataceae). Culture filtrates from the fungus 
were found to have antibacterial activity when injected 
directly into lesions caused by staphylococci and 
streptococci. Dr. Brotzu also demonstrated activity by 
intramuscular (IM) and intravenous (IV) administration 
3 
of the extracted filtrate into patients with 
brucellosis, typhoid, and paratyphoid fever. 
Following publication of his research in "The 
Works of the Institute of Hygiene of Cagliari", British 
bacteriologists at the Sir William Dunn School of 
Pathology became interested in his results. A culture 
sent to them was studied extensively and an extract was 
found to be a member of the steroid-triterpene group of 
compounds. This extract was named cephalosporin P 
since it was active only against Gram positive 
bacteria. An unstable hydrophilic substance was found 
in the aqueous phase with activity against Gram 
negative bacteria and, hence the designation 
cephalosporin N. Further studies on cephalosporin N 
showed that the compound was actually a penicillin; and 
its name was changed to penicillin N. During the 
purification of penicillin N, a third substance was 
discovered and named cephalosporin c. Cephalosporin C 
was the first cephalosporin compound with antimicrobial 
activity derived from this genus of fungi (Abraham, 
1979). 
Cepalosporins have a structural similarity to the 
penicillins (Fig. I A-B), including a beta lactam ring, 
and, hence, the name beta lactam antibiotics. They 
generally show resistance to penicillinase, and have a 
broader spectrum of activity. Cephalosporin C, 
7-aminocephalosporanic acid (7-ACA) (Figure I-A), 
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consists of a beta lactam ring and a dihydrothiazine 
ring. The large number of cephalosporins that have 
been introduced in the last 25 years have been the 
result of modifictions on position 3 of the 
dihydrothiazine ring and/or position 7 of the beta 
lactam ring. Changes at position 3 lead primarily to 
changes in the pharmacologic properties of the drugs 
-----
and, occasionally to changes in the bacterial activity 
(Neu 1982, 1983; Turck 1982; Garzone et. al. 1983; Rose 
and Barron 1983). Substitutions, additions and 
modifications, at position 7 alter the antibacterial 
activity and increase stability of the drugs to beta 
lactamases (Neu 1982, 1983; Garzone et. al. 1983). 
In contrast to the penicillins, only 
cephalosporins with an alpha aminoadipyl side chain can 
be obtained by fermentation. The methods used 
originally to obtain the nucleus of cephalosporin C 
yielded very small amounts, too small for commercial 
use. A breakthrough was achieved when Robert B. Morin 
and colleagues at Lilly Research Labs (Indianapolis, 
Indiana) produced 7-ACA by a chemical procedure, rather 
than by fermentation, and got a higher yield. This was 
a turning point in research on the cephalosporins 
(Abraham, 1979). 
The first cephalosporin, Cephalothin, was 
introduced in 1964, followed by the introduction of 
Cephaloridine in 1966, Cephaloglycin in 1970, 
5 
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Cephalexin and Cefazolin in 1971. The 1970's also 
witnessed the addition of Cephapirin, Cephradine, 
Cefadroxil, Cefaclor and Cephacetrile to name the most 
important members of what came to be called the first 
generation cephalosporins. The so-called second 
generation drugs made their appearance in the late 
1970's, with Cefamandole and Cefoxitin in 1979, to be 
followed in the 1980's by Ceforanide, Cefonicid and 
more recently Cefuroxime in 1983, and Cefotetan in 1986 
(McCue, 1985; Dr. Nahhas, 1987--personal 
communication). 
In the U.S.A. the first third generation 
cephalosporin, Cefotaxime, was marketed in 1981, and in 
1982 Moxalactam and Cefoperazone were introduced; 
\ 
Ceftizoxime became available in 1983 and Ceftazidime 
and Ceftriaxone in 1985. Soon to be released are 
Cefamenoxime and Cefsulodin; several others are under 
current clinical investigations or awaiting approval by 
the Federal Drug Administration. 
The classification into "generations" is unique to 
the cephalosporins; this terminology is not used with 
the penicillins, or other antimicrobial drugs. 
Initially it was based on marketing time. First 
generations came out first, then second, then third, 
although some second generations (Cefotetan and 
Cefuroxime), as indicated earlier, were marketed after 
the third generation group made its appearance. Today 
7 
the spectrum of activity against the various Gram 
negative and positive bacteria classifies the drugs 
into the three generations. The first generation (Fig. 
II) is most active chiefly against non-enteric gram 
positive cocci, and a limited number of Gram negative 
bacteria and anaerobes. Resistance to one first 
generation antibiotic usually means cross-resistance to 
all others in that category. 
The second generation cephalosporins (Fig. III) 
show improved activity against Gram negative bacteria 
but not against Pseudomonas. Third generation drugs 
(Fig. IV) have broader spectrum against gram negatives 
and in addition show various degrees of 
anti-Pseudomonas activity. Three of the third 
generation, (Cefotaxime, Ceftizoxime, and Moxalactam), 
are generally poor anti-Pseudomonas drugs, but 
excellent against other Gram negative bacilli. Some of 
the new drugs, such as Cefsulodin and Cefmenoxime, defy 
classification by the above scheme. It should be 
emphasized that, as the new generations of 
cephalosporins were developed with greater activity 
against Gram negative bacteria, their activity toward 
Gram positive organisms was reduced compared to that of 
the first and second generation cephalosporins. 
A few antibiotics which are considered 
cephalosporins actually do not conform to the true 
definition of the term as discussed earlier. 
8 
Cefotaxime, for instance, is a semi-synthetic 
cephalosporin, a methoxyimino derivative of 7-ACA. 
Cefoxitin which has some structural resemblance to 
Cefazolin is actually of the cephamycin group of 
antibiotics derived from a species of Streptomyces, £. 
lactamdurans, and not CephaJosporium. It differs from 
Cefazolin by having a methoxy group at position 7. 
Moxalactam, a synthetic 1-oxa-beta lactam, classified 
as a third generation drug, differs from other 
cephalosporins by the substitution of oxygen for the 
sulfur in position one of 7-ACA. Such a modification 
is now known to enhance antibacterial activity. It is 
also known that inclusion of the 7-methoxy group on the 
cephamycin molecule enhances stability to 
beta-lactamases, and addition of an alpha-carboxyl 
group increases antipseudomonal activity. This 
Structure-Activity relationship (SAR) is the basis of a 
new concept in designer drug research which has been 
responsible for the rapid and explosive developments of 
the new cephalosporins in recent years (Cunha and 
Ristuccia, 1982; Neu, 1983). 
It is beyond the scope of this investigation to 
report on the synthesis, pharmocologic, and clinical 
aspects of the cephalosporins. Figures II-IV show the 
structural formulae of the compounds investigated and 
the chemical differences alluded to earlier. 
The purpose of this study is to compare the 
activity of selected cephalosporins representing each 
of the three generation groups against certain Gram 
negative bacteria. Excluded from this study will be 
Gram positive bacteria, and certain Gram negative 
bacilli, such as species of Escherichia and Klebsiella, 
which are known to be uniformly susceptible to the 
first generation cephalosporins. The bacteria to be 
selected are Gram negative bacilli which are known to 
be resistant to first generation cephalosporins. These 
are to be tested for susceptibility to all the second 
and third generation cephalosporins that can be 
obtained. 
In the clinical laboratory, Cephalothin disks are 
used to determine susceptibility to all 10 first 
generation cephalosporins. In this study, both 
Cephalothin and Cefazolin disks will represent this 
group. There is some indication in the literature that 
some bacteria may be resistant to one but susceptible 
to the other. 
It should also be noted here that there are no 
studies in which all the cephalosporins (first, second, 
and third generations) were tested against the same 
strains at the same time. In this investigation twelve 
antibiotics (two first generation: Cephalothin, 
Cefazolin; four of the five second generatiod 1l: 
Cefoxitin, Cefamandole, Cefuroxime, Cefonicid; all six 
9 
third generation: Ceftazidime, Ceftizoxime, Cefotaxime, 
Cefoperazone, Ceftriaxone, Moxalactam) were tested. 
Certain studies have shown that an antibiogram, or a 
susceptibility pattern, can be used as an aid in the 
identification of certain bacteria (Nahhas, 
1985--personal communication). A second objective of 
this study will be to determine if such a pattern is 
found with respect to these twelve cephalosporins. 
1. Cefotetan, a new second generation cephalosporin, 
was not available until March 1987 and, therefore, was 
not tested except against three isolates of Campylobacter·jejuni. 
1 0 
MATERIALS AND METHODS 
Bacterial isolates 
One hundred forty-six strains of Gram negative 
bacilli recovered from various clinical sources were 
isolated at Dameron Hospital in Stockton, California 
between September 1986 and March 1987. Cultures were 
obtained on Tryptic Soy Agar (TSA), Gram stained when 
contamination was suspected, and reisolated on EMB or 
Hektoen agar plates to confirm purity. Single colonies 
were then subcultured on TSA slants (stock culture), 
incubated for 24 hours at 37°C, and stored in the 
refrigerator (2-8°C) for further studies. Some 
isolates were identified by the microbiologists at 
Dameron using a computerized identification system 
called Touch-Scan (Digital Biomedical Corporation, 
American Scientific Products, Sacramento, California); 
others identified or confirmed by me using the API20E 
(Analytab Products, Plainview, N.Y.) biochemical tests. 
Antibiotic Susceptibility 
Organisms were subcultured in TSA broth and 
incubated at 37'c for 2-5 hours and/or until growth 
density was equivalent to that of a MacFarlane 1.0 
Barium Sulfate standard. Using a sterile cotton swab, 
a small amount ofthe suspension was streaked on a 150 
x 15 mm Mueller-Hinton (M-H) plate to ensure an even 
11 
distribution of bacteria. The plate was left to dry at 
room temperature for about 5 minutes. Disks (Difco, 
Detroit, MI) were then applied using a 12-magazine-150 
mm dispenser (Difco). Plates were incubated at 37°C 
in an inverted position for approximately 16-18 hours 
before reading the results. Zones of inhibition were 
measured with a straight ruler and recorded. 
Interpretation of zones of inhibition was based on the 
National Committee for Clinical Laboratory Standards, 
(NCCLS) 1984 shown in Table I. 
The organisms selected for this study were all 
Gram negative bacilli representing 4 families: the 
species and number tested are as follows: Family 
Enterobacteriaceae: Proteus vulgaris (2), P. mirabilis 
(5), Proyidencia stuartii (6), X., alkalifaciens (5), 
Morganella morganii (16), Serratia marcescens (14), 
Enterobacter cloacae ( 17) , _£:__. aerogenes ( 9) , 
Citrobacter freundii (14), _Q_. diversus (3), .Q. 
amalonaticus (1), Yersinia intermedia (1), Y. 
enterocolitica (2), Kluyvera ascorbata (3); Family 
Pseudomonadaceae: Pseudomonas aeruginosa (31), ~· 
fluorescens (3); Family Neisseriaceae: Acinetobacter 
anitratus (3), b· lwoffi (1); Family Vibrionaceae: 
Aeromonas hydroohilia (4), Plesiomonas shigelloides 
(1), and Campylobacter jejuni (5). 
Antibiotic susceptibilities were determined 
according to standard procedures of the Kirby Bauer 
12 
method (Bauer et al, 1966), using Mueller-Hinton (M-H) 
agar. Bacto disks (Difco, Detroit, MI) of Cephalothin 
(30 ug), Cefazolin (30 ug), Cefamandole (30 ug), 
Cefoxitin (30 ug), Cefuroxime (30 ug), Cefonicid (30 
ug), Cefotaxime (30 ug), Ceftizoxime (30 ug), 
Ceftazidime (30 ug), Ceftriaxone (30 ug), Cefoperazone 
(75 ug), and Moxalactam (30 ug) were used. Cefotetan 
(30 ug) was not used to test all strains because it was 
not available until 1987. 
13 
RESULTS 
The in vitro activity of the cephalosporins is 
reported below and summarized in Tables II-VI. Tables 
II-A to VI-A show percent susceptible and intermediate 
susceptibility for each species; Tables II-B to VI-B 
--sh-0\<i-ti:ie--e-x-a-et---z-Gne-measu-rement-s -f-or ___ each __ .s_train __ . ____ 5_, 
I, and R are traditionally used by microbiologists to 
refer to susceptible, intermediate susceptibility, and 
resistant respectively. 
Proteus vulgaris 
Tables II A-B 
Based on two isolates, ..!:_. vulgaris is resistant 
to Cephalothin and Cefazolin. To the second 
generation, this species is resistant to Cefamandole, 
Cefuroxime, Cefonicid, but susceptible to Cefoxitin and 
to all the third generation drugs. 
Proteus mirabilis 
Tables II A-B 
All five strains were equally susceptible (100%) 
to the first, second and third generation drugs. 
14 
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Providencia stuartii 
Tables II A-B 
Six strains were found resistant to Cephalothin, 
but one strain (17%) was susceptible to Cefazolin. 
Eighty three percent were susceptible to Cefoxitin and 
Cefuroxime, and 100% susceptible to Cefamandole and 
Cefonicid, and to the third generation drugs. 
Providencia alkalifaciens 
Tables II A-B 
All five strains of...£... alkalifaciens were 100% 
susceptible to all three generation drugs except to 
Cephalothin for which 80% were susceptible and 20% 
intermediate. 
Morganella morganii 
Tables II A-B 
Sixteen strains were resistant to the first 
generation drugs. This study showed 44% susceptibility 
to Cefoxitin, 63% to Cefamandole, 56% to Cefonicid, and 
0% to Cefuroxime. One hundred percent susceptibility 
to the third generation drugs was seen. 
Serratia marcescens 
Tables III A-B 
None of the fourteen strains were susceptible to 
Cephalothin or to Cefazolin. Of the second generation 
drugs, some activity was exhibited by Cefoxitin (21% s 
other three drugs. Intermediate susceptibility was 
exhibited by 21% to Cefamandole. Although some 
activity was evident by Cefuroxime and Cefonicid, zones 
of 0-12 and 0-14 respectively, indicate resistance. 
Ninety-three percent of the strains were susceptible to 
Ceftazidime, Ceftizoxime, and Moxalactam. To 
Cefotaxime, Cefoperazone, and Ceftriaxone 86% showed 
susceptibility. 
Enterobacter cloacae 
Tables III A-B 
All seventeen strains were resistant to 
Cephalothin, Cefazolin, and to Cefoxitin. Fifty-three 
percent were susceptible to Cefamandole, 29% to 
Cefuroxime, and 47% to Cefonicid. To the third 
generation group 76% of the strains were susceptible to 
Ceftazidime, 65% to Ceftizoxime, 59% to Cefotaxime, 76% 
to Cefoperazone, 71% to Ceftriaxone, and 76% to 
Moxalactam. 
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Enterobacter aerogenes 
Tables III A-B 
All nine strains tested were resistant to 
Cephalothin. For Cefazolin 33% were susceptible. 
Twenty-two percent of my strains showed susceptibility 
to Cefoxitin, 89% to Cefamandole, 78% to Cefuroxime, 
and 78% to Cefonicid. Of the third generation, 89% 
were susceptible to Ceftazidime, Ceftizoxime, 
Cefotaxime, Cefoperazone, Ceftriaxone, and Moxalactam. 
As Table III-B indicates the strain that shows 
resistance and intermediate susceptibility to the third 
generation group is #9926 which was completely 
resistant not only to the first but also to the second 
generation drugs. 
Kluyvera ascorbata 
Tables III A-B 
Sixty-seven percent of the strains were 
susceptible to the first generation, but 100% to the 
second and third generation cephalosporins. 
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Citrobacter freundii 
Tables IV A-B 
Fourteen strains were resistant to Cephalothin 
(50% I) and 36% were susceptible (29% I) to Cefazolin. 
There was 86% susceptibility to all second generation 
drugs, except Cef0JCrttn----;-7%-~----N-trre-ty--t11r-e-e -per-cen--t----of--
my strains were susceptible to all the third generation 
drugs, except Cefoperazone (86%). 
Citrobacter diversus 
Tables IV A-B 
The three strains tested in this study showed 100% 
susceptibility to all three generations of antibiotics. 
Citrobacter amalonaticus 
Tables IV A-B 
The single strain was resistant to both first 
generation cephalosporins and to Cefamandole and 
Cefonicid of the second generation. It was susceptible 
to Cefoxitin and Cefuroxime, and to all third 
generation drugs, except Cefoperazone. 
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Yersinia intermedia 
Tables IV A-B 
The single strain of ~· intermedia was resistant 
to both Cephalothin and Cefazolin. The results were 
varied to the second generation, showing intermediate 
-----.,s·u-s-c-e-pt±-bi-1-±-ty-t-o--e-e-Eo x-i-ti B-, Bu--t- --ful-l- s_u s cep_ti bi_l i_t,y ____ 1;._Q 
Cefamandole. It was resistant to Cefuroxime and 
Cefonicid. The strain was susceptible to all third 
generation antibiotics tested. 
Yersinia enterocolitica 
Tables IV A-B 
The two strains tested in this study were 
resistant to both first generation drugs. One strain 
was susceptible to Cefoxitin, the other intermediate. 
There was 100% susceptibility to Cefamandole, 
Cefuroxime, Cefonocid and to all the third generation 
drugs. 
Pseudomonas aeruginosa 
Tables V A-B 
The 31 strains were resistant to the first and 
second generation cephalosporins. They were also 
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resistant to Ceftizoxime (29% I) and to Cefotaxime (77% 
I), but 90% susceptible to Ceftazidime, 81% to 
Cefoperazone, 6% to Ceftriaxone (68% I), and 13% to 
Moxalactam (71% I). 
Pseudomonas fluorescens 
Tables V A-B 
Three strains were resistant to the first and 
second generation and to Cefotaxime (67% I), 
Cefoperazone (67% I), Ceftriaxone (67% I), and 
Moxalactam of the third generation. There was 67% 
susceptibility to Ceftazidime (33% I) and 33% to 
Ceftizoxime (33% I). 
Acinetobacter anitratus 
Tables V A-B 
The results for three strains showed resistance to 
both Cephalothin and Cefazolin. For the second 
generation two strains were resistant to Cefoxitin, one 
intermediate. To Cefamandole and to Cefonicid all 
three were resistant. To Cefuroxime, one strain was 
susceptible, a second intermediate, and the third 
resistant. Three showed intermediate susceptibility to 
Cefotaxime, and two to Cefoperazone and Moxalactam of 
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the third generation, 100% susceptible to Ceftazidime, 
67% to Ceftizoxime (33% I), and 33% to Ceftriaxone (67% 
I) . 
Acinetobacter lwoffi 
Tables V A-B 
The single strain studied here was resistant to 
both first and second generation cephalosporins, except 
to Cefoxitin showing intermediate susceptibility and to 
Cefuroxime full susceptibility. The strain was also 
susceptible to Ceftazidime and Ceftizoxime, and 
intermediate to the other third generation drugs. 
Aeromonas hydrophilia 
Tables VI A-B 
Only one (25%) of the four strains of this species 
was susceptible to Cephalothin and Cefazolin, two 
(50%) to Cefoxitin and Cefonicid, and three (75%) to 
Cefamandole and Cefuroxime of the second generation. 
All four isolates were susceptible to the third 
generation drugs tested. 
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Plesiomonas shigelloides 
Tables VI A-B 
The single strain tested was susceptible to all 
three generations of cephalosporins. 
Campylobacter jejuni 
Tables VI A-B 
The five strains were resistant to the first and 
second generation cephalosporins, and to Cefoperazone, 
Ceftriaxone (100% I), and Moxalactam (40% I) of the 
third generation. Sixty percent were susceptible to 
Ceftazidime (40% I), 100% to Ceftizoxime, and 60% to 
Cefotaxime (40% I). 
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DISCUSSION 
Many mechanisms exist by which bacteria can become 
resistant to antimicrobial agents. These mechanisms 
fall into two general categories. Inherent resistance 
is due to a genetically determined insensitivity of a 
certain bacterium to a specific antimicrobial agent or 
group. Resistance of many Gram negative bacteria to 
Vancomycin and Rifampin, and resistance of enterococci 
to aminoglycosides are examples (Moellering, 1987). 
This resistance is believed to be due, at least partly, 
to inability of the antibicrobial to penetrate the cell 
wall and/or the cell membrane of the bacterium 
(Moellering, 1987). 
In acquired resistance, the genetic determinants 
are acquired by an organism previously known to be 
susceptible. 
This may be due to a mutation (natural mutation rate 
for bacteria is l0-6 to 161'3) or to a transfer of 
genetic material--chromosomal or extrachromosomal--from 
one bacterium to another via transposons, plasmids, and 
R factors. Neu (1982) indicates that mutational events 
are important in the development of resistance to some 
agents, but extrachromosomal genetic material in the 
form of plasmids is the most important factor in 
resistance. These plasmids are known to be transferred 
by conjugation, transformation, or transduction. 
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It is beyond the scope of this paper to go into a 
detailed discussion of the great variety of mechanisms 
that are reported in the literature. These mechanisms 
have been under active investigation since the late 
1970s, and most recently by Bush et al. (1985), Vu and 
Nikaido (1985), Werner et al. (1985), Kobayashi et al. 
(1986), Malouin and Bryan (1986), Neu et al. (1986), 
Phelps et al. (1986), Then and Angehrn (1986), Bayer et 
al. (1987), Mitsuyama et al. (1987), Naylor (1987), and 
Nicolas et al. (1987). Our present knowledge of 
cephalosporins suggests that the activity of these 
antimicrobial drugs to inhibit or kill bacteria depends 
on three factors: entry of the drugs through the cell 
wall, resistance to beta lactamases, and affinity for 
the enzymes involved in the peptidoglycan synthesis of 
the cell wall (Neu, 1982). 
The cell wall of Gram negative bacteria is a 
complex structure with pores through which substances 
with a molecular weight of less than 600 daltons can 
pass, provided the charge and the shape of the molecule 
are appropriate (Nikaido, 1979). Recent studies on 
Proteus mirabjJis, ~vulgaris, ~ morganij, 
Providencia rettgeri, and~. alcalifaciens, by 
Mitsuyama, et. al. (1987) suggested the presence of 
"porin proteins" with molecular weights of 37,000 and 
40,000 daltons which serve as channels with cation 
selectivity. Their work indicated that absence of this 
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protein may create a barrier effect on antibiotic 
permeation. Changes in the lipid content of the 
bacteria or in the binding together of the cell wall by 
cations such as magnesium and calcium can also affect 
the entry of an agent and thereby cause resistance 
(Neu, 1982). This was shown to occur in Pseudomonas 
and E. coli. 
-- - - ---
The second type of resistance mechanism, enzymatic 
inactivation, is exemplified by the beta lactarnases 
which include the cephalosporinases. These enzymes 
which can be plasmid- or chromosome-mediated may be 
either constitutive or inducible. Beta lactamases are 
degradative enzymes that exist in the periplasmic space 
between the outer cell membrane and the cell wall. 
Some investigators, according to Nayler (1987), 
believe that many Gram negative bacteria, if not all, 
contain chromosomal genes that code for low level 
production of beta lactamases and that in some species, 
particularly Enterobacter, exposure to beta lactams of 
the cephalosporin type may induce formation of much 
larger amounts of cephalosporinases. Sanders and 
Sanders (1979) expressed concern that widespread use of 
the newer broad-spectrum cephalosporins may lead to the 
emergence of highly resistant strains of Enterobacter, 
Serratia, and Pseudomonas. This prediction turned out 
to be accurate; Cefoxitin has been shown to induce 
resistance to other second generation cephalosporins by 
a number of investigators (Then and Angehrn, 1986; 
Bayer et al., 1987; Mitsuyama et al., 1987). 
The third factor relates to the enzymes involved 
in peptidoglycan synthesis. These enzymes are referred 
to in the literature as Penicillin-binding proteins or 
PBPs. If a beta lactam (penicillin or cephalosporin) 
should reach these proteins, the interaction may lead 
to either lysis of the bacterial cell, abnormal growth 
into long filaments or production of protoplasts and 
spheroblasts (Neu, 1982). 
The cephalosporins differ in their affinity to 
beta lactamases and to a large extent, the degree of 
this affinity determines how much of the agent reaches 
the PBPs (Neu, 1982). This quantitative relationship 
may be the reason for the differences in the activity 
of the cephalosporins (Neu, 1982). 
The discussion above indicates that to be 
effective, a cephalosporin must be able to penetrate 
the cell wall, resist cephalosporinases produced by the 
bacterial cell, and bind to its target molecules, the 
PBPs. It can, therefore, also be assumed that an 
alteration in a target PBP may lead to resistance. 
Malouin and Bryan (1986) reviewed the subject based on 
observations in several Gram positive bacteria and 
Neisseria gonorrhea. The authors found that such a 
modification also occurs in Pseudomonas aeruginosa 
during therapy. No such alterations have been reported 
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for the other Gram negative bacteria discussed in my 
studies. The exact mechanisms of alteration in the 
target PBP are not well-understood. 
Proteus 
Although .I_: vulgaris and .E._· mirabilis are members 
of- -tn-e---s-ame- g-enus-~-i-t- is --eviden-t that .their_ 
susceptibility to the first and second generation 
cephalosporins differs except with regard to Cefoxitin 
to which both are sensitive. This difference has been 
attributed in the past to different permeability 
characteristics of their cell walls. Recent studies by 
Mitsuyama et al. (1987:382) support this hypothesis, at 
least with respect to Cefoxitin. These investigators 
were able to induce resistance to Cefoxitin by exposing 
a strain to 50 ug/ml of Cefoxtin. They found that 
resistance was due to lack of an outer membrane protein 
in the mutants which they had produced experimentally. 
In the Cefoxitin-sensitive strain, this membrane 
protein or porin had aM. w. of 40,000 in~ mirabjlis 
and 37,000 in P. vulgaris. They suggested that these 
porins "form channels with cation selectivity" that 
permit the antibiotics to penetrate the cell. 
It is of interest to note that the response to the 
various antibiotics by both species has been either S 
or R. R, for resistance, was equivalent to 0 or 
complete zone of resistance (Table II B). If an 
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isolate can be identified as a member of the genus 
Proteus by colonial morphology and/or other 
morphological characteristics (it can be by an 
experienced microbiologist) then its antibiogram 
pattern, in the absence of spontaneous or induced 
resistance, can identify it on the basis of the first 
and second generation cephalosporins to the species 
level. The pattern for the "wild type" Proteus 
vulgaris is R R S R R R and that for~ mirabilis is S 
S S S S S representing Cephalothin, Cefazolin, 
Cefoxitin, Cefamandole, Cefuroxime, and Cefonicid 
resp.ectively. None of the seven strains in this genus 
demonstrate any evidence of resistance to the third 
generation cephalosporins, but this may be due to the 
small number of the collection, particularly ~. 
vulgaris. Since no resistance was evident to the first 
and second generation group by~. mirabilis, none would 
be expected to the third group. 
Providencia 
The genus Providencia is closely related to 
Proteus; in fact one species, Providencia rettgeri, 
has, until recently, been included in the genus 
Proteus. Both are, as indicated earlier, members of 
the Tribe Proteae. 
Table II-A suggests general resistance to the 
first generation cephalosporins by~· stuartii compared 
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to general susceptibility for .R_. alkalifaciens. Table 
II-B indicates that although all strains were 
resistant to Cephalothin, two (#8702-2 and 8863) showed 
slight response to the antibiotic, evident in a zone of 
9 mm in diameter instead of 0. The same two strains 
gave zones of 18 and 13 (S and R respectively) to 
Cefazolin indicating some ability to respond to this 
drug. 
Strain #6929 is of some interest; it was resistant 
(zone size 11) to Cefoxitin and intermediate to 
Cefuroxime (zone 17). An inhibition zone of 17 mm is 
the upper limit of "I" and only 1 mm smaller than 18 
for S for that antibiotic. I do not believe this is a 
technical error in procedure since all the other 
strains gave zones of 22 mm or higher for that 
antibiotic. It is probably a permeability problem and 
perhaps related to the resistance of that strain to 
Cefoxitin (zone of 11 mm). 11itsuyama et al. (1987) did 
not study this particular species in their 
investigation of the nature and characteristic of the 
outer membrane of Providencia. They studied .R_. 
rettgeri and~ alkalifaciens. Based on studies of 
induced Cefoxitin-resistant strains, they attributed 
resistance to Cefoxitin to be due to lack of porins 
which in the sensitive strains had a 11. w. of 37,000, 
similar to what they found in Proteus vulgaris. I do 
not believe that my data can shed any light on the 
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mechanism of resistance here, but it is obvious that 
there is a quantitative difference in response. 
Providencia alkalifaciens may be considered uniformly 
susceptible to the first generation group; Cephalothin 
seems to be less active in vitro that Cefazolin; a zone 
of 17 (I) by strain #8381 may be due to a heavy 
_____ ___:i,n_o_C':Jc!1JIItj i:!l()C:\l~ urn_ effect), resulting in a smaller zone 
(all the zones for that particular strain are smaller 
than corresponding zones for the other strains). 
No particular antibiogram pattern can be 
associated with the species except for their uniform 
resistance (~ stuartii) and susceptibility to 
Cephalothin (P. alkalifaciens). 
Morganella 
Until recently this species was a member of the 
genus Proteus. Penetration of antibiotics through the 
cell wall is also via the porin pores according to 
Mitsuyama et al. (1987). Interestingly, according to 
these investigators, 25 ug/ml of Cefoxitin, instead of 
50 ug/ml, was sufficient to induce resistance to 
Cefoxitin. Table II-B shows that 3 of the 16 strains 
which were completely resistant to Cefoxitin were also 
resistant to Cefamandole and Cefuroxime; whether the 
patients from whom these isolates were obtained were on 
Cefoxitin treatment was not investigated. 
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Although all the strains exhibited resistance to 
the first generation group, they do not show a definite 
pattern for the second generation. Cefuroxime seems to 
be the least effective in vitro. None showed any 
susceptibility to the drug, two (12.5%) gave a zone of 
17 (=I), four (25%) gave zero zone and nine (56%) zones 
of 10-16. In contrast, Cefamandole and Cefonicid seem 
-
to be the most active in vitro with 63% and 56% 
respectively. 
No resistance is evident in any of the isolates to 
the third generation drugs. Except for uniform 
resistance to the first generation cepahlosporins, no 
particular antibiogram pattern can be assigned to 
Morganella morganii. 
Serratia and Enterobacter 
The next three species, Serratia marcescens, 
Enterobacter cloacae, and E. aerogenes are members of 
the Tribe Klebsielleae. Serratia and Enterobacter 
share a number of common biochemical characteristics, 
as well as resistance to Cephalothin, Cefazolin, and 
Ampicillin. 
The nature of resistance to the beta lactam 
antibiotics in this group has been studied by Sanders 
and Sanders (1979) and more recently by Bush et al. 
( 1985) , Vu and Nikaido ( 1985) , Werner et al. ( 1985) , 
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Phelps et al. (1986), Then and Angehrn (1986), Nayler 
(1987), and Nicholas et al. (1987). These 
investigators agree that resistance is due to the 
production of an inducible chromosomally encoded 
cephalosporinase. 
Werner et al. (1985) studied chromosomal beta 
lactamases and outer membrane proteins of Enterobacter 
cloacae using mutants with altered beta lactamase 
expression derived from both patient-treated and 
laboratory induced strains. They reported that both 
beta lactamases and outer membrane proteins are 
significant determinants of the antibiotic 
susceptibility of the organism. They also observed 
that Cephalothin is a poor inducer of beta lactamase, 
whereas Cefoxitin is an excellent inducer of that 
enzyme and that high level resistance to Cefoxitin 
probably results from extensive induction of beta 
lactamase by the drug itself. As far as the outer 
membrane proteins are concerned, they (Werner et al, 
1985:458) concluded that "alteration in outer membrane 
proteins produced a moderate level of resistance to 
diverse beta lactam antibiotics." 
Then and Angehyn (1986:687) observed that "with 
the more frequent use of broad spectrum cephalosporins 
such as Cefamandole, Cefuroxime, Cefotaxime, and 
others, resistant strains of several Gram negative 
species, especially Enterobacter cloacae, have been 
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more frequently isolated." They also noted that "these 
strains exhibit a high level of resistance to almost 
all beta-lactam antibiotics" and that "resistance is 
restricted to beta lactam antibiotics and based on the 
production of large amounts of the derepressed 
(induced), chromosomally coded beta lactamase." They 
_______ al!;~_report;~(!_j:hat in !L_ cloacae "the frequency of 
mutation to the derepressed state is high and may be 
strain-specific.'' 
Nicolas et al. (1987:297) reported that "increased 
cephalosporinase production can be induced in vitro by 
exposing the bacteria to subclinical concentrations of 
some beta lactam antibiotics," and that removal of the 
antibiotic will lead to a decline in enzyme level, a 
phenomenon which they called "reversible behavior." 
Most of the studies on resistance have been done 
on Enterobacter cloacae: some of the literature 
implied, while others assumed that the same events 
occur in ~ aerogenes and Serratia marcescens. 
Serratia marcescens is notorious for its ability to 
develop resistance rapidly. A number of hospitals 
across the country have been plagued with isolates that 
show multiple resistance involving as many as 12 
antibiotics, representing every major antimicrobial 
group (Nahhas, 1987--personal communication). These 
particular strains, isolated prior to the introduction 
of the third generataion cephalosporin, are known to be 
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susceptible to three antibiotics only (Chloramphenicol, 
Nalidixic acid, and Amikacin). They are resistant to 
all commonly prescribed antibiotics, including 
Gentamycin and Tobramycin. One such strain was 
encountered in the course of this study (isolate 
#8816) . Table III-B shows its resistance pattern 
including the third generation cephalosporins. 
Unfortunately I had no access to the patient's record 
to find out what antibiotics were prescribed. 
Of the two species of Enterobacter', ~· cloacae 
shows greater resistance and a greater variation in its 
antibiogram pattern (Table III-A). All 17 strains were 
resistant to Cephalothin and Cefazolin in contrast with 
33% of E. aerogenes that were susceptible to Cefazolin 
though resistant to Cephalothin. E. cloacae was 100% 
resistant to Cefoxitin, 22% of~. aerogenes were 
sensitive. To the other three second generation 
cephalosporins, ~· cloacae showed 29-53% susceptibility 
compared with 78-89% for _E!..: aerogenes. To the third 
generation group 59-76% of E. cloacae were susceptible, 
compared with 78-100% for~· aerogenes. This study 
confirms what has appeared in the literature recently. 
Five strains in Table III-B, are of special interest. 
Strains #7447 and 7508 were isolated from one patient 
(N.H.) and strains 9183, 9327, and 9629 from another 
(M. s.) patient. 
N. H. was admitted to the Hospital and underwent 
abdominal surgery on September 11, 1986. On Sept. 13, 
an exudate from his abdominal wound was cultured which 
showed the presence of a large number of Enterobacter 
cloacae (#7447); the organism, as evident in Table 
III-B, was resistant to Cephalothin, Cefazolin, and 
Cefoxitin (typical pattern for a wild strain of E. 
cloacae) and susceptible to all the other antibiotics. 
Cefoxitin is often used in abdominal surgery because of 
its broad activity against many Gram negative bacilli, 
staphylococci, most streptococci, and Bacteroides spp. 
(anaerobic Gram negative bacilli which are common 
inhabitants of the intestine). The patient was 
continued on Cefoxitin because of concern about 
anaerobic infections. On Sept. 15, another specimen 
was taken (#7508) and a pure culture of~. cloacae was 
isolated. Table III-B shews that this isolate had 
become resistant to all three generations of 
cephalosporins except for Moxalactam, to which 
intermediate susceptibility was exhibited. Cefoxitin 
is known to induce resistance to the beta lactams 
(Moellering, 1987), but this is the only report 
suggesting that resistance involved this large number 
of cephalosporins at the same time. Strain #9592-2 
demonstrates a very similar phenomenon. 
The case of patient M. S. is even more 
interesting. She was admitted to the hospital for 
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extensive abdominal surgery (diverticulitis) in 
November, 1986, and placed on Cefoxitin. On November 
4, culture from the abdominal wound showed several 
types of bacteria including E. cloacae. As in the case 
of the first patient N.H., this isolate (#9183) showed 
resistance only to Cephalothin, Cefazolin, and 
Cefoxitin, intermediate susceptibility to Cefuroxime, 
but was fully susceptible to the other drugs, many of 
which exhibited zones of susceptibility much larger 
than the lower S range (23-30 mm) except for Cefonicid 
(low limit for S) and Cefuroxime (upper limit for I). 
Because of its resistance to Cefoxitin, the surgeon 
switched her to Cefotetan, that had just become 
available in the market. On Nov. 8, another culture 
was taken ( #9327) which also grew b cloacae. This 
isolate, as evident from Table III-B showed complete 
resistance to all the first and second generation 
cephalosporins; susceptibility of this strain to the 
third generation group was also affected; the strain 
showed only intermediate susceptibility to Ceftizoxime 
(18 mm zone), Cefotaxime, and Ceftriaxone (20 mm). It 
was still susceptible to the other three but the zones 
of inhibition compared with those for isolate #9183 
were smaller. When a third culture was taken on Nov. 
17 (#9629) the organism had become practically 
resistant to all three generation groups except for 
Cefoperazone and Moxalactam to which it showed 
intermediate susceptibility. Isolates from patient 
N. H. indicate that Cefoxitin can induce resistance to 
both the second and third generation groups. In 
patient M. s., it seems that Cefotetan played a similar 
role. When Cefotetan was introduced into the market, 
it was claimed (Moellering, 1987) not to induce 
resistance to other cephalosporins (Nahhas, 
1987--personal communication). 
Kluyvera 
This newly erected genus includes two species K. 
ascorbata and~ cryocrescens. Their habitat is 
described as "probably normal stool flora. Isolated 
from human infections, respiratory tract, blood, urine" 
(Finegold and Barron, 1986:400). My three isolates 
were from stools of children suffering from 
gastroenteritis. No antibiotics have been listed for 
this species in any of the literature that I reviewed 
for this study. My report may represent, if not the 
only, the most comprehensive record of susceptibilities 
to the cephalosporins. 
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Citrobacter 
The genus Citrobacter is represented by three 
species in this study: .£., freundii, £..,. diversus, and 
~ amalonaticus. Table IV A and B show their 
antibiotic patterns. c. amalonaticus is rarely 
encou-nt:er-e-a---in---cJ:inica-}:--- specimens;- the singl-e- isolate __ _ 
reported here shows resistance to Cephalothin, 
Cefazolin, Cefarnandole, and Cefonicid and 
susceptibility to Cefoxitin and Cefuroxime and all the 
third generation group. Whether this is a typical 
antibiogram for this species is not known since there 
was nothing in the literature to compare with. 
Antibiograms from other medical centers and hospitals 
do not include rare organisms. In contrast the three 
isolates of ~. diversus are typical in their antibiotic 
pattern, i.e. susceptibility to all the cephalosporins. 
Citrobacter freundii shows an inconsistent pattern 
of in vitro reponse to the first generation 
cephalosporins; it is also known to be resistant to 
Cefoxitin. Nicolas et al. (1987:296) summarized our 
knowledge on resistance of this species to the beta 
1actams. They attributed resistance to a "host 
spontaneous chromosomal mutation with a frequency of 10-5 
-6 
-10 occurring both during antibiotic therapy and in 
the laboratory. n 
The present study shows that only one strain 
(isolate #8861) was resistant to all three generations 
of the drugs. Unfortunately the medical history of the 
patient with this isolate was not available to 
determine what factor(s) might have contributed to this 
high degree of resistance. At the same time, these 
results indicate that just as we have seen with other 
bacteria discussed so far, the third generation 
cephalosporins are not immune to inactivation by some 
old or new mechanisms of resistance that can be 
developed by bacteria. 
Yersinia 
The genus Yersinia is represented by 2 species: 
Y. intermedia (one strain) and~· enterocolitica (two 
strains). Y. intermedia may not be a pathogen; Y. 
enterocolitica produces gastroenteritis accompanied by 
bloody stools and symptoms resembling appendicitis. 
Finegold and Barron (1986:421) state that "Yersinia are 
susceptible tho chloramphenicol, aminoglycosides, 
tetracycline and trimethoprim-sulfamethoxazole." No 
cephalosporins are listed. 
Scavizzi et al. (1987) studied in vitro and in 
vivo activities of Cefotaxime on Y. enterocolitica. 
They reported in vitro susceptibility of the organism 
to this third generation drug. They found, however, 
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that even at high doses (250 mg/kg body weight), 
Cefotaxime was totally ineffective in mice. Scavizzi 
et al. (1987:525) quoted several studies done mostly in 
France that showed that :f._. enterocolitica was resistant 
to Cephalothin and to "related beta lactam antibiotics 
because of synthesis of beta lactamases, but it was 
susceptible in vitro to the third generation group 
including Cefotaxime." They had no explanation for the 
discrepancy between in vitro and in vivo activitiy. 
Because "it is not possible to explain, from any given 
property of the antibiotic, the bacteria, or the host," 
they recommended delaying use of the newer beta lactam 
antibiotics in treatment. My study confirms the in 
vitro susceptibility of both species of Yersinia to the 
third generation cephalosporins, and to Cefamandole of 
the second generation; Y. enterocolitica, but not~· 
intermedia, was also susceptible to Cefuroxime and 
Cefonicid. 
Pseudomonas 
The Pseudomonads and particularly J:_. aeruginosa 
have always been of concern in hospitals not only 
because of their role in nosocomial infections but also 
because of their lack of susceptibility to most of the 
common antimicrobials used. 
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Resistance of P. aeruginosa has been the subject 
of many studies, too numerous to even list. A review 
of these articles has recently been presented by 
Stratton and Tausk (1987). Their conclusions follow. 
Some of the resistance mechanisms to beta lactam 
antibiotics, as indicated earlier, are related to entry 
of a drug into the cell whereas others involve its 
removal by beta lactamases. The outer membrane of P. 
aeruginosa is highly impermeable to most antibiotics 
because of the small size of the porin pores. High 
levels of beta lactamase production is due either to 
the presence of a plasmid or to the derepression of a 
formerly inducible, chromosomally encoded beta 
lactamase. Mutational alterations in the beta lactam 
targets, penecillin binding proteins (PBPs) have also 
been reported. 
Although each of these mechanisms plays a role and 
each is important, entry of the drug into the cell and 
its removal by beta lactamases, working in concert, can 
produce greater resistance than would be produced by 
either mechanism alone. Stratton and Tausk (1987) also 
emphasize the importance of the relationship between 
rate of diffusion and characteristics of the antibiotic 
molecules such as size, charge, and presence of bulky 
side chains. 
Beta lactamases are normally present in the 
periplasmic space of P. aeruginosa and their 
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concentration increases during treatment or exposure to 
the drugs in vitro. A drug that penetrates the outer 
membrane rapidly, however, is less affected by increase 
in beta lactamases than one that enters slowly. Since 
the antibiotics differ in their charges, sizes, and 
side chains, they diffuse at different rates. 
Furthermore, their ability to induce beta lactamase 
production varies. The nature and role of PBPs are 
less understood. 
As far as the 31 isolates of P. aeruginosa and the 
three strains of ~· fluorescens encountered in this 
study are concerned, it is evident that they show 
complete resistance to the first and second generation 
cephalosporins. Table V-A shows that of the six drugs, 
Ceftazidime and Cefoperazone are most active in vitro 
against ~ aeruginosa. Cefotaxime and Moxalactam are 
less effective. Table V-B shows that there are no 
isolates resistant to Ceftazidime that are susceptible 
to other drugs in that group. In contrast, one strain 
of~ fluorescens showed intermediate susceptibility to 
Ceftazidime but was fully susceptible to Ceftizoxime. 
The line between S and I, and I and R, in 
Pseudomonas testing is very thin. The size of 
inhibition zone is highly influenced by the density of 
the inoculum. This is far more critical in this group 
than in the others presented in this paper. The 
interpretation of the results should be very 
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conservative especially in borderline measurements. 
One may not get the same zone size when the test is 
repeated with only a slightly lower or slightly higher 
concentration of the organisms than in a previous test. 
It is also unfortunate that it was not possible to 
study the effect of antibiotic treatment on development 
of resistance in this group since no two strains in 
this group of 31 isolates came from the same patient. 
Comparison as was done for Enterobacter cloacae is, 
therefore, not possible. 
Acinetobacter 
It was unexpected to find an organism susceptible 
to a second generation drug but showing intermediate 
susceptibility to a third generation cephalosporin. 
Table V-B shows this is the case with A. anitratus 
isolate #9936 and A. lwoffi isolate #7586. Only a 
larger collection will determine the accuracy or 
plausibility of these results. 
The genera Aeromonas and Plesiomonas are Gram 
negative bacilli that are currently assigned to the 
Family Vibrionaceae on the basis of polar flagellation 
and a positive oxidase test. Their normal habitat is 
fresh and brackish water. Aeromonas hydrophilia is 
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known as a pathogen in fish and reptiles. Aeromonas 
and Plesiomonas have been implicated as opportunistic 
pathogens in immunocompromised and immunosuppressed 
patients, persons with hepatobiliary disease, and 
leukemias. Their role in gastrointestianl disease and 
in otherwise healthy individuals is not clear. 
Aeromonas 
Little is known about the antibiotic pattern of 
this rarely encountered organism. In a recent review, 
Holmberg and Farmer (1984) of the Center for Disease 
Control, At·lanta, Georgia indicated that the isolates 
that have been named Aeromonas hydrophilia may actually 
represent eight or nine species or at least distinct 
groups based on DNA-DNA hybridization studies. The 
authors indicate that~. hydrophilia are almost always 
resistant to Ampicillin and Penicillin and are usually 
resistant to carbenicillin, erythromycin, and 
cephalosporins. No specific cephalosporins were 
listed. 
Whether the differences seen in the response to 
the first and second generation cephalosporins are due 
to the presence of more than one "species" or "group" 
among my four isolates cannot be determined. The data 
simply suggests that before a cephalosporin of the 
first or second generation group is to be used 
therapeutically, it must be tested for susceptibility. 
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Plesiomonas :"'-
Holmberg and Farmer (1984:636) indicate that 
"separate in vitro studies of the susceptibility of P. 
shigelloides to antibicrobial agents have not been 
done, but all 19 isolates of~ shigelloides referred 
to the CeE~~r for Disease Control from 1977 through 
1983 were resistant to penicillin, ampicillin' and 
carbenicillin." No reference is made to the 
cephalosporins. If no other studies have been done 
since this 1984 report, this report stands as the only 
one available. 
Campylobacter 
The inclusion of these five isolates was a 
decision made near the end of the project. This 
organism with unusual cultural requirements (42°C 
incubation, reduced oxygen tension and increased CO 
concentration) is the most common cause of enteric 
infection in the United States today. Treatment of 
Campylobacteriosis utilizes erythromycin as the drug of 
choice and tetracycline as a second choice (20% of the 
strains are resistant; tetracycline should not be given 
to children under 7 years of age). The organism is 
susceptible to few other drugs but the only 
cephalosporin indicated is Cefotaxime (Finegold and 
Barron, 1986). This study confirms the ineffectiveness 
----
of the first and second generation cephalosporins. 
Cefoperazone is ineffective, and Moxalactam and 
Ceftriaxone are not very good. This study shows that 
only 60% of the strains are susceptible to Cefotaxime 
and Ceftazidime but 100% to Ceftizoxime. The 
incubation conditions listed above do not represent an 
acceptable standard for susceptibility studies and, 
therefore, the results can be considered presumptive 
only. 
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